Tag: astellas-pharma

MD Anderson, Astellas Pharma sign option agreement for monoclonal antibody drug targeting acute myeloid leukemia

| April 3, 2015 | 0 Comments

( University of Texas M. D. Anderson Cancer Center ) The University of Texas MD Anderson Cancer Center and Astellas Pharma Inc.

Continue Reading

U.S. FDA Approves New Indication for the Use of XTANDI(R) (Enzalutamide) Capsules for Patients With Metastatic …

| September 10, 2014 | 0 Comments

Medivation, Inc. and Astellas Pharma Inc. announced today that the U.S.

Continue Reading

Cancer Research UK and Cancer Research Technology Join Forces with Astellas on Autophagy to Find New Cancer Treatments

| August 8, 2014 | 0 Comments

TOKYO, Aug. 8, 2014 /PRNewswire/ — Cancer Research UK and its commercial arm, Cancer Research Technology (“CRT”), are to join forces with Astellas Pharma Inc. (Tokyo, President & CEO: Yoshihiko Hatanaka, “Astellas”) to find new drug targets in the fight against cancer, with an initial focus on pancreatic cancer.

Continue Reading

XTANDI™ (Enzalutamide) Authorized in the European Union for Advanced Prostate Cancer

| June 24, 2013 | 0 Comments

CHERTSEY, England & SAN FRANCISCO–(BUSINESSWIRE)– Astellas Pharma Europe Ltd., the European Headquarters of Tokyo-based Astellas Pharma Inc. (TSE:4503), and Medivation, Inc. (Nasdaq: MDVN) announced …

Continue Reading

XTANDI™▼ (Enzalutamide) Authorised in the European Union (EU) for Advanced Prostate Cancer

| June 24, 2013 | 0 Comments

Today, Astellas Pharma Europe Ltd., the European Headquarters of Tokyo-based Astellas Pharma Inc. , and Medivation, Inc

Continue Reading

AVEO and Astellas Announce FDA Advisory Committee To Review Tivozanib for the Treatment of Advanced Renal Cell Carcinoma

| February 27, 2013 | 0 Comments

AVEO Oncology and Astellas Pharma Global Development, Inc., a U.S.

Continue Reading

New Class of Treatment for Overactive Bladder Approved in Europe

| January 11, 2013 | 0 Comments

Astellas Pharma Europe Limited: Chertsey, England (ots/PRNewswire) – A new treatment, BETMIGA(TM) (mirabegron) has received approval from the European Commission (EC) for the treatment of overactive bladder (OAB) symptoms in adults.[1] Mirabegron represents the first new class of …

Continue Reading